Table 3.
Characteristics of CHF patients with CC-AAbs positive and negative.
| Characteristics | DCM (n = 732) | P | ICM (n = 1099) | P | ||
|---|---|---|---|---|---|---|
| CC-AAb(+) (n = 43) | CC-AAb(−) (n = 689) | CC-AAb(+) (n = 51) | CC-AAb (−) (n = 1048) | |||
| Age (years) | 59.14 ± 13.61 | 58.84 ± 14.48 | 0.895 | 67.69 ± 12.26 | 67.88 ± 10.39 | 0.899 |
| Male gender, n (%) | 34 (79.07%) | 524 (76.05%) | 0.869 | 40 (78.43%) | 845 (80.63%) | 0.898 |
| MHR (beats/min) | 79.29 ± 17.98 | 79.71 ± 18.95 | 0.883 | 74.73 ± 18.21 | 72.46 ± 14.16 | 0.273 |
| Hypertension, n (%) | 11 (25.58%) | 231 (33.53%) | 0.434 | 30 (58.82%) | 642 (61.26%) | 0.863 |
| Hyperlipidemia, n (%) | 3 (6.98%) | 73 (10.60%) | 0.793 | 18 (35.29%) | 256 (24.43%) | 0.191 |
| Diabetes mellitus, n (%) | 5 (11.63%) | 115 (16.69%) | 0.452 | 15 (29.41%) | 302 (28.82%) | 0.946 |
| PVC, n (%) | 14 (32.56%) | 178 (25.83%) | 0.467 | 7 (13.73%) | 210 (20.04%) | 0.353 |
| AF, n (%) | 11 (25.58%) | 166 (24.09%) | 0.864 | 4 (7.84%) | 126 (12.02%) | 0.415 |
| QRS duration (ms) | 110.71 ± 35.66 | 113.82 ± 38.41 | 0.610 | 103.25 ± 22.58 | 104.96 ± 42.76 | 0.777 |
| QTc (ms) | 463.61 ± 67.32 | 445.50 ± 104.37 | 0.268 | 452.41 ± 95.50 | 444.10 ± 88.34 | 0.514 |
| NYHA | ||||||
| II | 11 (25.58%) | 146 (21.19%) | 0.590 | 25 (49.02%) | 557 (53.15%) | 0.746 |
| III | 18 (41.86%) | 288 (41.80%) | 0.996 | 17 (33.33%) | 321 (30.63%) | 0.768 |
| IV | 14 (32.56%) | 255 (37.01%) | 0.685 | 9 (17.65%) | 170 (16.22%) | 0.820 |
| LVEF (%) | 33.46 ± 7.63 | 32.88 ± 9.92 | 0.718 | 41.38 ± 8.40 | 41.31 ± 8.69 | 0.958 |
| LVEDD (mm) | 66.87 ± 8.99 | 66.06 ± 12.13 | 0.686 | 56.10 ± 7.57 | 57.66 ± 9.31 | 0.254 |
| BNP (pg/mL) | 2139.17 ± 336.68 | 2089.10 ± 367.98 | 0.385 | 1984.44 ± 308.64 | 1982.79 ± 396.77 | 0.971 |
| Treatments | ||||||
| ACEI, n (%) | 26 (60.47%) | 411 (59.65%) | 0.958 | 34 (66.67%) | 676 (64.50%) | 0.884 |
| Diuretic, n (%) | 36 (83.72%) | 529 (76.77%) | 0.710 | 37 (72.55%) | 704 (67.18%) | 0.728 |
| Digoxin, n (%) | 35 (81.40%) | 448 (65.02%) | 0.340 | 34 (67.94%) | 663 (65.29%) | 0.826 |
| β-blockers, n (%) | 37 (86.05%) | 533 (77.36%) | 0.646 | 41 (80.39%) | 735 (70.13%) | 0.817 |
| CCBs, n (%) | 3 (6.98%) | 21 (3.05%) | 0.182 | 11 (21.57%) | 237 (22.61%) | 0.889 |
| ICD, n (%) | 2 (4.65%) | 8 (1.16%) | 0.119 | 3 (5.88%) | 25 (2.39%) | 0.147 |
Values are mean ± SD or number (%). P < 0.05 was considered significant comparing with NSCD group. PVC indicated frequent premature ventricular beats (more than 3000 beats/24 h). AF: atrial fibrillation; ACEI: angiotensin-converting enzyme inhibitor; BMI: body mass index; CHF: chronic heart failure; NYHA: New York Heart Association; CC-AAbs: calcium channel autoantibodies; DCM: dilated cardiomyopathy; ICM: ischaemic cardiomyopathy; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; MHR: mean heart rate; ICD: implantable cardioverter defibrillator; SCD: sudden cardiac death; NSCD: nonsudden cardiac death.